A new analysis of 3,713 patients with non-small cell lung cancer (NSCLC) suggests that the stage of cancer affects how well EGFR-TKI drugs work and how tolerable they are. The study compared early-stage and advanced-stage patients who received EGFR-TKI monotherapy, a type of targeted therapy.
Researchers found that the objective response rate (ORR), meaning the proportion of patients whose tumors shrank, was higher in advanced-stage patients (0.59) compared to early-stage patients (0.36). However, the disease control rate (DCR), which includes stable disease, was slightly higher in early-stage patients (0.95 vs 0.89).
Safety also differed by stage. Early-stage patients had a significantly lower incidence of severe (Grade 3 or higher) treatment-related adverse events (8.0%) compared to advanced-stage patients (21%). This suggests that early-stage patients may tolerate the treatment better.
The study is a meta-analysis, which combines results from multiple studies, but it does not explain why the response rate is higher in advanced-stage patients. This is a limitation, and the findings should be interpreted with caution. The results suggest that treatment strategies might need to be tailored by stage, possibly combining TKIs with other treatments in early stages, but more research is needed.
For patients and doctors, this analysis highlights that stage is an important factor in how well EGFR-TKIs work and how they are tolerated. It does not provide specific guidance for individual treatment decisions, so patients should discuss their options with their oncologist.
